MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
about
Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gammaHonokiol: a non-adipogenic PPARγ agonist from natureIdentification and Mechanism of 10-Carbon Fatty Acid as Modulating Ligand of Peroxisome Proliferator-activated ReceptorsOn the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal musclesInvestigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Regulation of chemokine and chemokine receptor expression by PPARγ in adipocytes and macrophagesThiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.Multi-tissue, selective PPARγ modulation of insulin sensitivity and metabolic pathways in obese rats.Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditureRevisiting PPARγ as a target for the treatment of metabolic disordersIdentification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes.Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptorsActivation of PPARγ by a Natural Flavonoid Modulator, Apigenin Ameliorates Obesity-Related Inflammation Via Regulation of Macrophage PolarizationNF-kappaB signaling: multiple angles to target OA.Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease.Selective Inhibition of PTP1B by Vitalboside A from Syzygium cumini Enhances Insulin Sensitivity and Attenuates Lipid Accumulation Via Partial Agonism to PPARγ: In Vitro and In Silico Investigation.PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein.Regulation of chemokine and chemokine receptor expression by PPARG in adipocytes and macrophages.Dihydrosanguinarine Enhances Glucose Uptake in Mouse 3T3-L1 Cells.Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ.Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP-activated protein kinase (AMPK) signaling
P2860
Q24599833-0CF2A0C0-1CA6-414F-AEAD-7B867E70B4C7Q24614114-223A4D58-0A8B-48AA-A801-7DF0708FCFA7Q27675297-CDD58D82-9FB8-4D54-9DC0-8E94CE02901DQ27697692-ECE759BE-C3BA-4524-9B5F-0F0067084616Q30426407-B8560ED2-D6FD-460E-A4C5-456063D85F39Q34243620-89158274-C9E2-413E-97E7-C1CAA176EA91Q34315432-29D48F26-0798-4F10-BBA8-B7AC0C3F3F89Q34330155-F3D20574-A7F2-4DEA-B04D-2A93F36F5DEEQ34501727-F1CDF32D-F578-48EA-BBC9-020E0A29A98CQ34502676-0C66B54D-A544-46F1-AE2B-34D7CD064175Q34798213-27F1B2C9-227D-4AC7-848C-D9D2C5A356E2Q35237706-2130A0FE-AF69-4879-A86A-20043877FE51Q35842216-56BF5B85-AA3D-4872-8FFF-DFA2910C159BQ36684873-71ACD715-B2D4-4538-807D-14E3C1B60DF5Q36733873-C4BBD80A-AF90-428F-A15D-2047F73AC6E1Q37149978-EF3058AE-5285-464F-8CAA-038F0438EE0EQ37701897-F00B4F2E-2811-4032-8356-BC1A0BBC2A75Q37724195-0B540F3A-A33F-4A1A-B577-69FEB02503B4Q37992099-BC38D988-4807-459A-8700-36ABCA3BA969Q38595252-644EFBD5-F6F0-4958-89BA-18FEC727B58DQ38785251-C1EDE114-A9F2-4080-BA9B-07806E2BE2BAQ41893963-B352D94E-12DB-4523-A9D8-A05DB07C355EQ46089881-A30DE724-3069-48DD-BCF4-C99859235809Q47095014-C1833E7C-3788-4C27-92F0-7E8391886C33Q47130302-83A0C809-E56C-48F2-B99F-F98E1DF57600Q58761757-562203A7-B200-44FA-BFDC-F1B58252BEF6
P2860
MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
MBX-102/JNJ39659100, a novel p ...... ence of weight gain and edema.
@ast
MBX-102/JNJ39659100, a novel p ...... ence of weight gain and edema.
@en
type
label
MBX-102/JNJ39659100, a novel p ...... ence of weight gain and edema.
@ast
MBX-102/JNJ39659100, a novel p ...... ence of weight gain and edema.
@en
prefLabel
MBX-102/JNJ39659100, a novel p ...... ence of weight gain and edema.
@ast
MBX-102/JNJ39659100, a novel p ...... ence of weight gain and edema.
@en
P2093
P2860
P356
P1476
MBX-102/JNJ39659100, a novel p ...... ence of weight gain and edema.
@en
P2093
Brian E Lavan
Dennis Rentzeperis
Dorothy D Sears
Fang Zhang
Francine M Gregoire
Holly J Clarke
James Lenhard
L Edward Clemens
Svetlana Favelyukis
Thomas A Gustafson
P2860
P304
P356
10.1210/ME.2008-0473
P577
2009-04-23T00:00:00Z